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The Clinical Significance of Occult Gastrointestinal Primary Tumours in
Metastatic Cancer: A Population Retrospective Cohort Study
Original Article
Purpose
The purpose of this study was to estimate the incidence of occult gastrointestinal (GI) pri-
mary tumours in patients with metastatic cancer of uncertain primary origin and evaluate
their influence on treatments and overall survival (OS). 
Materials and Methods
We used population heath data from Manitoba, Canada to identify all patients initially diag-
nosed with metastatic cancer between 2002 and 2011. We defined patients to have “occult”
primary tumour if the primary was found at least 6 months after initial diagnosis. Otherwise,
we considered primary tumours as “obvious.” We used propensity-score methods to match
each patient with occult GI tumour to four patients with obvious GI tumour on all known clin-
icopathologic features. We compared treatments and 2-year survival data between the two
patient groups and assessed treatment effect on OS using Cox regression adjustment. 
Results
Eighty-three patients had occult GI primary tumours, accounting for 17.6% of men and 14%
of women with metastatic cancer of uncertain primary. A 1:4 matching created a matched
group of 332 patients with obvious GI primary tumour. Occult cases compared to the
matched group were less likely to receive surgical interventions and targeted biological ther-
apy, and more likely to receive cytotoxic empiric chemotherapeutic agents. Having an occult
GI tumour was associated with reduced OS and appeared to be a nonsignificant independ-
ent predictor of OS when adjusting for treatment differences. 
Conclusion
GI tumours are the most common occult primary tumours in men and the second most
common in women. Patients with occult GI primary tumours are potentially being under-
treated with available GI site-specific and targeted therapies.
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Introduction
According to the Canadian Cancer Society, gastrointestinal
(GI) cancer is the most common type of cancer and cause of
cancer death in Canada [1]. In 2016, 46,000 Canadians will be
diagnosed with cancers of the GI tract involving the esopha-
gus, stomach, biliary system, pancreas, small intestine, colon,
rectum, and anus and 22,000 Canadians will die from these
cancers [1]. The tendency of GI cancers to be either asymp-
tomatic at early stages or to present with vague symptoms
that might be mistaken for other inflammatory diseases at
more advanced stages, as well as the lack of accurate screen-
ing procedures for many of these cancers, contribute to the
diagnosis of GI cancers at more advanced-stages, often after
they metastasize to other areas of the body [2].
Patients with metastatic cancers of the GI tract may have
clinical and pathologic presentation masking their actual GI
tract origin (i.e., occult GI tumour). A series of recent analyses
of gene profiling molecular assays predicted the GI tract to
be the most common cancer site of origin in patients initially
diagnosed with metastatic cancer of unknown origin, 
accounting for 34% to 45% of these patients [3-5]. In a small
number of case reports, metastatic disease of occult GI pri-
mary tumours have also been shown to have clinicopatho-
logic features that mimic metastatic disease from other
cancer sites of origin leading to a diagnostic and thus treat-
ment conundrum [6-14]. It is essential to correctly distinguish
a GI primary site from metastatic disease of other primary
sites not only for selection of a growing arsenal of effective
first-line site-specific or targeted therapies which may 
improve survival [15], but also for the selection of second-
line chemotherapy, decisions regarding debulking surgery
or surgery for resection of metastases, optimal management
of symptoms, prognosis, and recommendations regarding
entry into hospice care. 
Currently, little is known about the clinical significance of
metastatic disease of occult GI primary tumours in actual
clinical practice. In this study, we used provincial heath 
administrative databases in the Canadian province of Mani-
toba to identify occult GI primary tumours in patients with
metastatic cancer of uncertain primary (i.e., difficult to diag-
nose primary) and estimate their actual incidence. We also
aimed to compare those patients to their counterparts of 
patients with metastatic disease of obvious (i.e. readily diag-
nosed) GI primary tumours to evaluate the impact of having
an occult GI primary tumour on disease management and
overall survival. 
Materials and Methods
1. Data sources and identification of study population
We conducted a retrospective cohort study using admin-
istrative health data obtained by linking the databases of the
Manitoba Cancer Registry (MCR) and Provincial Pharmacy
program of CancerCare Manitoba (CCMB) with Manitoba
Health’s administrative databases, including the Hospital
Discharge Database, Physician Claims Database and the
Drug Program Information Network (DPIN).  A full descrip-
tion of these databases, their contents and the linkage process
has been reported elsewhere [16-19]. 
We used the MCR to identify all metastatic cancer patients
(defined as stage IV or distant metastasis within 4 months of
initial diagnosis) during the period from January 1, 2002, to
December 31, 2011. All Manitoba residents aged 18 to 90
years old with no history of cancer at diagnosis who had
their metastatic disease histologically confirmed and sur-
vived at least 6 months following their initial cancer diagno-
sis were eligible for inclusion in our metastatic patient
population. This 6-month window was important to ensure
that patients would have had reasonable survival time dur-
ing the early course of their metastatic disease to undergo a
full diagnostic workup and have their primary tumour site
identified [20]. When the primary tumour was identified 6
months or more after initial diagnosis, we defined patients
to have “occult” primary tumour (i.e., metastatic cancer of
uncertain primary). Otherwise, we defined patients to have
“obvious” primary tumour. Our case definition is consistent
with other attempts at identifying occult primary tumours
[20]. Full details regarding the identification of our metastatic
patient population are reported elsewhere [21].
For this analysis, we used our metastatic patient popula-
tion to identify all patients diagnosed with metastatic cancer
of GI sites including esophagus, gastroesophageal junction,
stomach, small intestine, colon, rectum, anus, anal canal,
liver, intra hepatic bile duct, extra hepatic bile duct, gallblad-
der, pancreas, and other unspecified GI tract. We stratified
this group into two main subgroups: (1) patients with occult
GI tumours and (2) patients with obvious GI tumours. Two-
year follow-up information was collected from the MCR for
each patient in the two subgroups including surgical and
therapeutic radiology procedures, systemic therapies, pallia-
tive care, diagnosis of second primary and death. 
We linked those patients with the Provincial Pharmacy
Program of CCMB and Manitoba Health’s administrative
databases to validate all cancer therapy data captured by the
MCR; to collect additional information on types of radiother-
apy, chemotherapy, and targeted cancer therapy agents as
described elsewhere [16-19]; and to measure co-morbidity
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using the method developed by Charlson et al. [22] and used
elsewhere [18,19,21]. We also used, in particular, the Physi-
cian Claims Database to collect information on GI diagnostic
examinations received during the diagnostic workup (defi-
ned as the period from 6 months before to 6 months after can-
cer diagnosis) for all identified patients diagnosed with
metastatic cancer of GI sites. The GI diagnostic examinations
recorded in the Physician Claims Database included diag-
nostic laparoscopy or laparotomy, diagnostic GI endoscopic
examinations (i.e., esophagoscopy and esophagogastroduo-
denoscopy, gastroscopy, enteroscopy, endoscopic ultra-
sound, colonoscopy, and proctosigmoidoscopy), taking of
biopsy from a GI site, abdominal ultrasound, computerized
axial tomography (CT) scan of the abdomen, magnetic reso-
nance imaging (MRI) scan of the abdomen, and GI nuclear
scans.
Ethics approval for the study was obtained from the Uni-
versity of Manitoba Health Research Ethics Board, Manitoba
Health Information Privacy Committee and University of
Western Ontario Health Research Ethics Board. 
2. Statistical analysis 
Continuous data are reported as mean±standard devia-
tion, and categorical data, as numbers and percentages. Cat-
egorical data were compared using the chi-square test.
Quantitative variables were compared using the t test. All
statistical tests were two-sided and results were considered
significant at the 5% critical level. Statistical analysis was per-
formed using SAS ver. 9.3 (SAS Institute Inc., Cary, NC). 
We performed a matched analysis within our cohort study.
We used logistic regression to create a propensity score (i.e.,
likelihood) [23] for having occult GI primary tumour, using
the following potential confounders, which were available
for the entire cohort: age, sex, Charlson co-morbidity score,
number and type of metastatic sites, grade differentiation,
primary tumour site, histology, and year of initial diagnosis,
regardless of their individual statistical significance. We used
the propensity score to match each patient who had an occult
GI tumour with up to four patients who had obvious GI 
tumour on the estimated propensity score. To avoid a poor
quality match, we only considered observations that were
within a ±0.01 of the occult unit’s propensity score for match-
ing and chose the closest match without replacement (i.e.,
caliper matching without replacement) [23]. When no
matches were found that case would be dropped. 
Time to death was assessed using Kaplan-Meier survival
curves. The curves were compared using the log-rank test
statistic. Cox proportional hazard modeling was used to cal-
culate hazard ratios (HRs) with associated 95% confidence
intervals (CIs) to assess the differences between occult cases
and the matched group with respect to 2-year overall sur-
vival (OS). We tested the effect of cancer treatments on the
calculated HR for cases with occult versus matched patients
with obvious GI primary tumours. We included receipt of
surgical resection (no vs. yes), radiotherapy (no vs. yes), and
systemic therapy (i.e., chemotherapy or biological targeted
therapy) (no vs. yes) as covariates in a Cox proportional haz-
ard model. We also tested the interactions between these 
covariates and status of primary tumour (occult vs. obvious
GI tumour). In subgroup analyses in which we included 
patients from the case and matched groups who were treated
with a given cancer therapy, we examined the effect of wait
time after initial diagnosis to receive that cancer treatment
and the effect of receipt of certain type of therapeutic agents
versus others on OS. 
In separate analyses we used Kaplan-Meier survival
curves and Cox regression to compare the 2-year OS in the
case group of patients with occult GI tumours to all patients
with obvious GI primary tumours and generate HR. We con-
ducted standard adjusted analyses by including all potential
confounders mentioned earlier in this section as covariates
in a Cox proportional hazard model. We also used the
propensity score to adjust for differences in baseline charac-
teristics between the two patient groups using two methods.
First, we used the propensity score as a covariate in a Cox
proportional hazard model and generate adjusted HR [23].
Second, we used a weighted Cox proportional hazards
model and generate adjusted HR, where the weight assigned
for each patient was based on the stabilized inverse propen-
sity score as previously described [24].
Results
There were 529 patients who had metastatic cancer of 
uncertain primary origin (i.e., had an occult primary tumour),
accounting for 8.9% of all patients newly diagnosed with
metastatic cancer who met the inclusion criteria (n=5,953)
(Table 1). Of those, there were 83 patients with occult GI pri-
mary tumour, accounting for 15.7% of all patients with
metastatic cancer of uncertain primary and 5% of all patients
with metastatic GI primary tumour (n=1,656) (Table 1). 
Prior to matching, patients with metastatic cancer of occult
GI primary tumours presented with distinctive clinicopatho-
logic features from their counterparts of all patients with 
obvious GI primary tumours (n=1,573) (Table 2). Using 1:4
matching on the estimated propensity score, we matched the
case group of 83 patients with occult GI primary tumours with
a group of 332 patients with obvious GI primary tumours. No
occult cases were dropped due to poor match quality. Table 2
shows the baseline patient and tumour characteristics of the
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matched group (n=332) as compared to the case group of 83
patients with occult GI primary tumours. As a result of match-
ing, we eliminated differences in age, sex, year of initial diag-
nosis, co-morbidity score, grade differentiation, GI primary
tumour location, histology, and number and type of metastatic
sites between occult cases and the matched group (Table 2).
Compared to the matched group, occult cases experienced on
average a longer time of 10.8 months after initial cancer diag-
nosis to have their primary tumour identified (Table 2). Dur-
ing the diagnostic workup, occult cases compared to the
matched group received similar diagnostic laparoscopies or
laparotomies and abdominal diagnostic imaging examina-
tions. However, occult cases were less likely to receive any
type of diagnostic GI endoscopic examinations (mean differ-
ence, 33.4%; 95% CI, 21.8 to 45; p < 0.001) including upper GI
endoscopy (mean difference, 14.5%; 95% CI, 4.5 to 24.9;
p=0.01), lower GI endoscopy (mean difference, 14.2%; 95% CI,
2.8 to 25.5; p=0.01), endoscopic ultrasound (mean difference,
15%; 95% CI, 10.5 to 19.7; p < 0.001), and endoscopic retro-
grade cholangio-pancreatography (mean difference, 13%; 95%
CI, 7.9 to 18; p < 0.001) (Table 2). 
1. Treatment characteristics
Receipt of systemic therapy and time to radiotherapy and
systemic therapy after initial diagnosis did not differ signifi-
cantly between the occult cases and matched group (Table 3).
Occult cases compared to matched patients were less likely to
have surgical resections (mean difference, 20.2%; 95% CI, 8.5
to 31.8; p=0.001) and receive radiotherapy (mean difference,
15.7%; 95% CI, 6 to 25.3; p=0.005) (Table 3). Among all patients
who had surgical resections, the time to surgery was longer
for cases compared to matched patients (mean difference, 1
month; 95% CI, 0.17 to 1.85; p=0.01) (Table 3). Among all 
patients who received systemic therapy, cases were more
likely to receive platinum drugs (mean difference, 20.7%; 95%
CI, 5.3 to 36.1; p=0.01), anthracyclines (mean difference, 15.7%;
95% CI, 3.4 to 28.1; p=0.002) and taxanes (mean difference,
8.9%; 95% CI, 3 to 18.5; p=0.01) and less likely to receive bio-
logical targeted therapy (mean difference, 18%; 95% CI, 8.7 to
27.3; p=0.005) than matched patients (Table 3). Among 
patients who received biological targeted therapy, cases were
more likely to receive bevacizumab (mean difference, 16%;
95% CI, 6.8 to 25.2; p=0.01) compared to the matched group
(Table 3). Table 3 shows the treatment characteristics of cases,
matched group with obvious GI tumours and all patients with
obvious GI tumours (n=1,573). 
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Patients with obvious Patients with occult All patients
primary tumour primary tumour diagnosed withPrimary tumour site
Men Women All Men Women All metastatic 
(n=3,157) (n=2,267) (n=5,424) (n=244) (n=285) (n=529) cancer (n=5,953)
Gastrointestinal tumours 960 (30.4) 613 (27.0) 1,573 (29.0) 43 (17.6) 40 (14.0) 83 (15.7) 1,656 (27.8)
Lung and pleural tumours 607 (19.2) 604 (26.6) 1,211 (22.3) 21 (8.6) 21 (7.4) 42 (7.9) 1,253 (21.0)
Urological tumours 910 (28.8) 89 (3.9) 999 (18.4) 39 (16) 6 (2.1) 45 (8.5) 1,044 (17.5)
Lymphoma tumours 266 (8.4) 211 (9.3) 477 (8.8) 10 (4.1) 10 (3.5) 20 (3.8) 497 (8.3)
Head and neck tumours 279 (8.8) 91 (4.0) 370 (6.8) 18 (7.4) 3 (1.1) 21 (4.0) 391 (6.6)
Gynecologic tumours - 265 (11.7) 265 (4.9) - 55 (19.3) 55 (10.4) 320 (5.4)
Breast tumours 1 (< 0.1) 280 (12.4) 281 (5.2) 0 ( 4 (1.4) 4 (0.7) 285 (4.8)
Unknown primary tumour site - - - 99 (40.6) 129 (45.2) 228 (43.1) 228 (3.8)
(primary tumour never diagnosed)
Melanoma (skin) tumours 57 (1.8) 25 (1.1) 82 (1.5) 6 (2.4) 6 (2.1) 12 (2.3) 94 (1.6)
Bone and soft tissue sarcoma tumours 35 (1.1) 41 (1.8) 76 (1.4) 6 (2.4) 6 (2.1) 12 (2.3) 88 (1.5)
Endocrine tumours 38 (1.2) 44 (1.9) 82 (1.5) 2 (0.8) 4 (1.4) 6 (1.1) 88 (1.5)
Ophthalmic tumours 2 (< 0.1) 4 (0.2) 6 (0.1) 0 ( 0 ( 0 ( 6 (0.1)
Ill-defined tumours 1 (< 0.1) 0 ( 1 (< 0.1) 0 ( 1 ( 1 (0.2) 2 (< 0.1)
Brain tumours 1 (< 0.1) 0 ( 1 (< 0.1) 0 ( 0 ( 0 ( 1 (< 0.1)
Table 1. Primary tumour site of 5,953 patients diagnosed with metastatic cancer by sex and diagnostic status of primary 
tumour
Values are presented as number (%).
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Table 2. Baseline patient and tumour characteristics of 1,656 patients diagnosed with metastatic GI cancer by diagnostic
status of their primary tumours
Patients with Patients with Matched patients 




tumours (n=1,573) tumours (n=83) (n=332)b)
Age at initial diagnosis (yr)
Mean±SD (range) 64±12.5 (19-90) 62±11.7 (36-90) 0.18 62±10.9 (35-90) 0.90
Year of initial diagnosis
2002-2003 269 (17.1) 14 (16.9) 0.60 57 (17.2) 0.90
2004-2005 299 (19.0) 12 (14.5) 50 (15.06)
2006-2007 360 (22.9) 16 (19.3) 68 (20.5)
2008-2009 332 (21.1) 22 (26.5) 84 (25.3)
2010-2011 313 (19.9) 19 (22.9) 73 (21.98)
Type of GI diagnostic examination 
received during the diagnostic workupd)
Diagnostic laparoscopy or laparotomy 104 (6.6) 10 (12.04) 0.05 32 (9.6) 0.50
Upper GI endoscopy 488 (31.02) 19 (22.9) 0.10 124 (37.3) 0.01
Lower GI endoscopy 989 (62.9) 26 (31.3) < 0.001 151 (45.5) 0.01
Endoscopic retrograde  93 (5.9) 2 (2.4) 0.10 51 (15.4) 0.001
cholangio-pancreatography
Endoscopic ultrasound 138 (8.8) 1 (1.2) 0.01 54 (16.3) < 0.001
Any type of GI diagnostic  1,286 (81.7) 37 (44.6) < 0.001 259 (78.01) < 0.001
endoscopic exanimation
Taking of biopsy from a GI site 609 (38.7) 17 (20.5) < 0.001 86 (25.9) 0.30
Abdominal ultrasound 415 (26.4) 34 (40.96) 0.003 118 (35.5) 0.30
CT scan of the abdomen 1,275 (81.05) 71 (85.5) 0.30 264 (79.5) 0.20
MRI scan of the abdomen 283 (17.99) 14 (16.9) 0.80 67 (20.2) 0.50
GI nuclear scan 2 (0.12) 0 ( > 0.99 1 (0.3) > 0.99
Sex
Men 960 (61.02) 43 (51.8) 0.09 175 (52.7) 0.90
Women 613 (38.97) 40 (48.2) 157 (47.3)
GI primary tumour site
Esophagus and gastroesophageal junction 159 (10.1) 9 (10.8) < 0.001 38 (11.4) 0.90
Stomach 96 (6.1) 4 (4.8) 16 (4.8)
Small intestine 31 (1.97) 6 (7.2) 26 (7.8)
Colon, rectum, anus, and anal canal 1,101 (69.99) 35 (42.2) 140 (42.2)
Liver and intrahepatic bile duct 23 (1.46) 3 (3.6) 14 (4.2)
Gallbladder 18 (1.1) 2 (2.4) 8 (2.4)
Extrahepatic bile duct 16 (1.01) 7 (8.4) 25 (7.5)
Pancreas 127 (8.07) 15 (18) 63 (18.9)
Unspecified GI tract 2 (0.13) 2 (2.4) 2 (0.6)
Grade differentiation
Well differentiated moderately 65 (4.1) 6 (7.2) < 0.001 24 (7.2) 0.90
Moderately differentiated 826 (52.5) 18 (21.7) 73 (21.9)
Poorly differentiated 296 (18.8) 18 (21.7) 73 (21.9)
Undifferentiated 386 (24.6) 41 (49.4) 162 (48.8)
Histology
Adenocarcinomas 1,307 (83.08) 57 (68.6) 0.003 225 (67.8) 0.90
Cystic, mucinous and serous 121 (7.69) 13 (15.7) 55 (16.5)
Squamous, other epithelial, 145 (9.2) 13 (15.7) 52 (15.6)
unspecified epithelial, other non-epithelial
and undifferentiated
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Table 2. Continued
Patients with Patients with Matched patients 




tumours (n=1,573) tumours (n=83) (n=332)b)
Time interval between initial 
cancer diagnosis and identification 
of primary tumour (mo)
Mean±SD (range) 0.24±0.95 (0-5.9) 11±4 (6.1-22.9) < 0.001 0.30±1 (0-5.8) < 0.001
No. of patients (%)
" 0 to < 3 1,505 (95.7) 0 ( 313 (94.3)
" 3 to < 6 68 (4.3) 0 ( 19 (5.7)
" 6 to < 9 0 ( 32 (38.6) 0 (
" 9 to < 12 0 ( 21 (25.3) 0 (
" 12 to < 15 0 ( 17 (20.5) 0 (
" 15 to < 24 0 ( 13 (15.6) 0 (
No. of metastatic sites 
1 452 (28.7) 32 (38.5) 0.07 127 (38.2) 0.90
2 757 (48.4) 27 (32.5) 112 (33.7)
3 267 (16.9) 19 (22.8) 74 (22.2)
" 4 88 (5.6) 5 (6.02) 19 (5.7)
Metastatic sites
Digestive system 1,690 (39.9) 82 (38.3) 0.001 237 (38.9) 0.90
Respiratory system 645 (15.2) 35 (16.3) 97 (15.9)
Female genital system 52 (1.2) 14 (6.5) 39 (6.4)
Bones and joints 146 (3.5) 20 (9.3) 54 (8.9)
Lymph nodes 1,376 (32.5) 52 (24.3) 146 (24.0)
Buccal cavity and pharynx, 326 (7.7) 11 (5.1) 36 (5.9)
male genital system, 
urinary system, brain, endocrine, 
soft tissue (including heart), skin, 
hematopoietic and reticuloendothelial 
systems, others and ill-defined
With second primary tumour 60 (3.8) 0 ( 0.07 0 ( > 0.99
Charlson co-morbidity scoree)
Mean±SD (range) 0.30±0.77 (0-11) 0.21±0.58 (0-4) 0.30 0.22±0.6 (0-4) 0.90
Score > 0 344 (21.9) 14 (16.9) 0.30 60 (18) 0.80
0 1,229 69 272
1 271 12 48
" 2 73 2 12
Values are presented as number (%) unless otherwise indicated. GI, gastrointestinal; SD, standard deviation; CT, computed
tomography; MRI, magnetic resonance imaging. a)Patients with occult (n=83) vs. all obvious (n=1,573) using Fisher exact or
chi-square, b)Patients were matched on the estimated propensity score, c)Patients with occult (n=83) vs. matched obvious
(n=1,573) using Fisher exact or chi-square, d)Diagnostic workup was defined as the period from 6 months before to 6 months
after metastatic cancer diagnosis, e)Co-morbid diagnoses were considered present if they were found during 1 year before
and 6 months after the initial diagnosis with cancer. 
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Table 3. Treatments of 1,656 patients diagnosed with metastatic GI cancer by diagnostic status of their primary tumours
Patients with Patients with Matched patients 




tumours (n=1,573) tumours (n=83) (n=332)b)
With surgical resection 1,055 (67.4) 30 (36.0) < 0.001 187 (56.3) 0.001
Time interval between initial cancer 
diagnosis and surgical resection (mo)
Mean±SD (range) 1.2±2.2 (0-20.1) 1.9±4.2 (0-20.5) 0.09 0.8±1.6 (0-12.6) 0.01
" 0 to < 3 953 ( 25 ( 175 (
" 3 to < 6 60 ( 2 ( 8 (
" 6 to < 12 29 ( 2 ( 4 (
" 12 to < 24 11 ( 1 ( 0 (
With radiotherapy 468 (29.7) 15 (18.0) 0.02 112 (33.7) 0.005
Time interval between initial cancer diagnosis
and start of radiotherapy (mo)
Mean±SD (range) 6.1±5.6 (0-24) 6.4±5.1 (0.6-15) 0.80 7.6±6.7 (0.3-24) 0.50
" 0 to < 3 161 ( 5 ( 33 (
" 3 to < 6 147 ( 3 ( 29 (
" 6 to < 12 94 ( 5 ( 24 (
" 12 to < 24 66 ( 2 ( 26 (
Type of radiotherapy
Teletherapy 346 (73.9) 11 (73.3) 0.90 87 (70.6) 0.90
Other types 122 (26.1) 4 (26.7) 33 (29.4)
With systemic therapy 1,176 (74.8) 59 (71.1) 0.45 261 (78.6) 0.10
Time interval between initial cancer 
diagnosis and start of systemic therapy (mo)
Mean±SD (range) 3.4±3 (0-23.6) 3.5±4.5 (0-22.9) 0.90 3.4±3.4 (0-23.6) 0.90
" 0 to < 3 693 ( 41 ( 162 (
" 3 to < 6 359 ( 10 ( 70 (
" 6 to < 12 89 ( 4 ( 18 (
" 12 to < 24 35 ( 4 ( 11 (
With information about systemic 876 (74.5) 46 (77.9) 0.50 200 (76.6) 0.80
therapy agents received
Frequency of systemic therapy 
agents received
Single agents 130 (14.8) 10 (21.7) 0.40 55 (27.5) 0.60
Double agents 370 (42.3) 17 (36.9) 77 (38.5)
Triple agents or more 376 (42.9) 19 (41.3) 68 (34.0)
Type of chemotherapeutic agents received
Antimetabolitesd) 841 (96.0) 44 (95.6) 0.90 190 (95.0) 0.90
Topoisomerase inhibitorse) 490 (55.9) 24 (52.2) 0.60 91 (45.5) 0.40
Platinum drugsf) 537 (61.3) 30 (65.2) 0.60 89 (44.5) 0.01
Anthracyclinesg) 57 (6.5) 10 (21.7) 0.004 12 (6.0) 0.002
Taxanesh) 26 (2.9) 5 (10.8) 0.01 4 (2.0) 0.01
Others agentsi) 26 (2.9) 1 (2.2) 0.90 5 (2.5) 0.90
With biological targeted therapy 176 (20.1) 3 (6.5) 0.02 49 (24.5) 0.005
Type of biological targeted 
therapy agents received
Bevacizumab 149 (17.0) 3 (6.5) 0.06 45 (22.5) 0.01
Cetuximab 18 (2.0) 1 (2.1) 0.90 8 (4.0) 0.90
Panitumumab 11(1.3) 0 ( 0.90 3 (1.5) 0.90
Other targeted therapy 3 (0.3) 0 ( 0.90 0 (
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2. Survival outcomes 
Cases had worse OS compared to matched patients (2-year
OS, 30% vs. 41.3%, p=0.01; median OS, 14.2 months vs. 20.3
months, Fig. 1) (HR, 1.44; 95% CI, 1.1 to 1.9; p=0.01) (Table 4).
In a Cox proportional-hazard regression analysis, having an
occult compared to an obvious GI tumour became a nonsignif-
icant independent predictor of OS when controlling for use of
surgery, radiation therapy and chemotherapy (Table 4). In this
analysis, receipt of surgical resection and chemotherapy were
significant independent predictors of OS (Table 4). No inter-
actions between treatment and primary tumour status (occult
vs. obvious) were identified. 
In subgroup analyses, the time from diagnosis to surgery
was a significant independent predictor of OS in patients
treated with surgery (HR for one month increase in wait time,
1.09; 95% CI, 1.04 to 1.16; p=0.01). The times from diagnosis to
receipt of radiation therapy and systemic therapy were not sig-
nificant independent predictors of OS. Similarly, the type of
chemotherapeutic agents received (platinum, taxanes and 
anthracyclines vs. other chemotherapeutic combinations) was
not an independent significant predictor of OS in patients
treated with chemotherapy. However, receipt of biological tar-
geted therapy was associated with survival advantage in 
patients treated with systematic therapy from the case and
matched group (HR, 0.5; 95% CI, 0.08 to 0.83; p=0.001).
Unadjusted and adjusted Cox proportional-hazard regres-
sion analyses that compared OS of the case group of 83 
patients with occult GI primary tumours to all patients with
obvious GI primary tumours (n=1,573) revealed similar results
(Table 4, Fig. 1). 
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Table 3. Continued
Patients with Patients with Matched patients 




tumours (n=1,573) tumours (n=83) (n=332)b)
With support drugs received to 774 (88.4) 32 (69.6) < 0.001 151 (75.5) 0.40
control side effects or conditions 
associated with chemotherapy
Values are presented as number (%) unless otherwise indicated. GI, gastrointestinal; SD, standard deviation. a)Patients with
occult (n=83) vs. all obvious (n=1,573) using Fisher exact or chi-square, b)Patients were matched on the estimated propensity
score, c)Patients with occult (n=83) vs. matched obvious (n=332) using Fisher exact or chi-square, d)Antimetabolites included
capecitabine, gemcitabine, 5-fluorouracil, and raltitrexed, e)Topoisomerase inhibitors included etoposide and irinotecan, f)Plat-
inum drugs included carboplatin, cisplatin, and oxaliplatin, g)Anthracyclines included doxorubicin and epirubicin, h)Taxanes
included paclitaxel and docetaxel,  i)Other agents included dexamethasone, vincristine, streptozocin, cyclophosphamide, and
mitomycin. 
Fig. 1. Overall survival analyses comparing patients with
occult gastrointestinal (GI) primary tumours to patients
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Patients with occult GI primary tumours (58 deaths)
Matched patients with obvious GI primary tumours (195 deaths)
All patients with obvious GI primary tumours (849 deaths) 
46%
Stratified log-rank test p < 0.01 at 2 years
41.3%
30.1%
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Discussion
To our knowledge, the present study is the first to deter-
mine the incidence of metastatic cancer of occult GI primary
tumours through a population-based analysis. With GI can-
cers being the most frequent occult primary tumours identi-
fied in men and the second most frequent in women with
metastatic cancer of uncertain primary, oncologists should
maintain a high index of suspicion in GI origins of disease
when conducting clinical, surgical, pathological, and radio-
logical evaluations of these patients. It is necessary to under-
stand the natural history of GI cancers because the incidence,
prognosis, and recommended treatment of these tumours
vary with anatomical location and histological subtype.
The absence of accurate determination of GI primary 
tumours early in the course of metastatic cancer appears to
be associated with fewer diagnostic GI endoscopic examina-
tions during the diagnostic workup, less frequent surgical 
intervention and use of biological targeted therapy such as
bevacizumab, longer time to surgical interventions and
greater use of empiric (i.e., broad-spectrum) and more toxic
chemotherapeutic drugs such as platinum drugs, taxanes
and anthracyclines. Less exposure to surgery and biological
targeted therapy and a longer time to receive surgery were
all independently associated with higher risk of death and
appeared to account for a large portion of the observed 45%
increase in risk of mortality for patients with occult GI 
tumours. This association should be interpreted with caution
as it might also be due to unexplained differences in tumour
biology, disease burden and/or the functional status of 
patients differing between cases and the matched group.
However, it is still reasonable to hypothesize that many 
patients were rendered unsuitable for certain effective and
targeted cancer treatment and treated with more intensive
empiric cytotoxic chemotherapy for their metastatic disease
due to the uncertainty of primary tumour site. The implica-
tion is that with the growing availability of more effective
personalized treatments, it is important to determine GI pri-
mary tumour sites early in the course of metastatic disease
for timely use of the best systemic and local treatment to 
optimize patients’ survival and quality of life. The current
Canadian clinical practice has not been influenced by the 
recently emerged gene expression profiling assays to help
identify the primary tumour in metastatic cancer [4,25-27].
These techniques complement current traditional diagnostic
procedures (e.g., immunohistochemical analyses, endo-
scopies, CT scans, X-rays, MRI scans, etc.) when dealing with
diagnostic difficulties so that the primary tumour can be clas-
sified early in the course of metastatic disease [28,29].
A precision medicine approach can often be applied to the
treatment of metastatic GI cancers [15]. There are now 10 
biological targeted therapies for these cancers that have been
approved by the U.S. Food and Drug Administration for clin-
ical use (e.g., cetuximab, panitumumab, and bevacizumab
for colorectal cancer, trastuzumab, and regorafenib for gas-
tric and gastroesophageal cancer) and many others are in
various phases of development [15]. Generally, these tar-
geted therapies are studied, approved, and reimbursed
solely within the context of an identified GI primary tumour
location. In addition, selection of these treatments is not only
dependent on the biologic characteristics of individual GI 
tumour (e.g., KRAS mutation and anti-epidermal growth fac-
tor receptor status) but also on knowledge of GI primary 
tumour sites to interpret mutation results. For instance,
knowledge of KRAS mutation status has quite different 
implications depending on whether the primary site is lung
versus colon. Therefore, information about the GI primary
tumour location and its inherent biologic characteristics are
both necessary and complementary for patients to access
new personalized treatments of metastatic GI cancers.
Although this is a retrospective cohort study and our 
results must be considered hypothesis generating, the inci-
dence of occult GI primary tumours and their impact on ther-
apeutic decision making and patient outcomes are unlikely
to be studied in prospective designed analyses. This is 
because metastatic cancer of occult GI source by definition
cannot be identified a priori and the size of any prospective
investigation would be too large to be feasible and would
take several years to complete. Furthermore, the randomiza-
tion of metastatic patients potentially considered to have 
occult GI primary tumours to different treatment modalities
might not be considered ethical due to the existence of site-
specific therapies and the possibility other therapeutic strate-
gies might be less effective. Our retrospective cohort study
is an example of an alternative approach. This study used
rigorous linkage of high quality population data from com-
prehensive heath administrative databases and yielded true
incidence rates of occult GI primary tumours. We have taken
special care to avoid sources of bias and confounding in our
study by conducting a matched cohort analysis where the
matched patient group with obvious GI tumours clearly had
the same underlying population as the cases with occult GI
tumours and were matched on all known patient and 
tumour characteristics. In fact, the smaller number of patients
included in our matched cohort analysis compared to our
overall cohort permits future investigation of more detailed
and expensive risk factors of having an occult GI tumour. For
instance, important factors associated with diagnostic
workup obtained from detailed medical histories or biologic
markers such as specialist referrals and type and frequency
of immunohistochemistry tests (i.e., information not col-
lected by the databases used for this study) become feasible
to investigate in order to understand the actual diagnostic
192 CANCER  RESEARCH  AND  TREATMENT
Malek B. Hannouf, Occult Gastrointestinal Tumours
barriers in patients with occult GI tumours. 
In conclusion, GI tumours are the most common occult pri-
mary tumours detected in men and the second most common
detected in women presenting with metastatic cancer of 
uncertain primary. Currently, patients with occult GI pri-
mary tumours are potentially being undertreated with avail-
able GI site-specific and targeted therapies. It may be
beneficial to determine the occult GI primary tumour site
early in the course of metastatic cancer to enable more effec-
tive therapies and improve survival outcomes.
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